The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolisation, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the shedding of Lawsonia intracellularis bacteria associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

The disclosure provides native outer membrane vesicle (NOMV) vaccines containing a coronavirus receptor binding domain (RBD) modified to be a lipoprotein. Also provided are compositions comprising a meningococcal strain having a plasmid-borne gene encoding the SARS-CoV-2 RBD modified to be a lipoprotein. Also provided are a meningococcal strain and a NOMV vaccine containing a plasmid coding for the SARS-CoV-2 RBD with a promoter/enhancer and polyA sequence that provide for expression of the RBD in mammalian cells.

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

The present invention relates i. a. to an immunogenic composition comprising: a) one or more antigens of avibacterium paragallinarum and one or more antigens of avian encephalomyelitis virus and one or more antigens of fowl pox virus; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by avibacterium paragallinarum, avian encephalomyelitis virus and fowl pox virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

The present invention relates to the treatment of coronavirus infections and to preparing subjects for such an infection by administering a parapoxvirus. This treatment is to assist the immune system in combatting the virus and to thereby prevent and to ameliorate symptoms of coronavirus disease.

Disclosed herein are immunogenic compositions (e.g., vaccines) for use in the treatment of mycobacteria infections and biomarkers for monitoring of therapeutic responsiveness to the immunogenic compositions in a subject (e.g., a human). In a first aspect, the disclosure features a pharmaceutical composition containing between 1×10{circumflex over ( )}2 CPU and 1×10{circumflex over ( )}10 CPU of a Mycobacterium tuberculosis strain (Mtb) with one or more mutations that ablate or reduce expression of LprG and Rv1410 (ΔLprG Mtb) in a volume of between 0.05 mL and 3 mL.

Provided herein are methods and compositions related to EVs useful as therapeutic agents.